Document Detail


Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.
MedLine Citation:
PMID:  23252565     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Monoclonal antibodies (mAbs) - rituximab, ofatumumab and alemtuzumab - have been approved for use in the therapy of chronic lymphocytic leukemia (CLL). Recently, a new generation of anti-CD20 mAbs has become available for preclinical studies and clinical trials. These antibodies were engineered to have augmented antitumor activity by increasing complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity and Fc-binding affinity for the low-affinity variants of the Fcγ receptor IIIa. The most promising mAb directed against CD20 is obinutuzumab (GA-101). mAbs directed against CD22, CD37 and CD40 have also shown some activity in CLL. In addition, small modular immunopharmaceuticals - TRU-015 (anti-CD20) and TRU-016 (anti-CD37) - that retain Fc-mediated effector functions have been developed and investigated in preclinical studies and clinical trials. Antibody-drug conjugates and recombinant immunotoxins are also being evaluated in lymphoid malignancies. Further studies will elucidate the role of these agents in the treatment of CLL.
Authors:
Tadeusz Robak
Related Documents :
24746155 - Development of monoclonal antibodies to interrogate functional domains and isoforms of ...
11087445 - Production, characterization, and application of anti-gossypol polyclonal antibodies.
1311735 - Caveats for the use of surface-adsorbed protein antigen to test the specificity of anti...
25006715 - Affinity-based precipitation via a bivalent peptidic hapten for the purification of mon...
2679335 - Relation of antinuclear fluorescence patterns and titres to autoantibody prevalence.
7028625 - Human neutrophil swelling induced by immune complexes and aggregated igg.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Future oncology (London, England)     Volume:  9     ISSN:  1744-8301     ISO Abbreviation:  Future Oncol     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101256629     Medline TA:  Future Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  69-91     Citation Subset:  IM    
Affiliation:
Department of Hematology, Medical University of Lodz, 93-510 Lodz, Ul. Ciolkowskiego 2, Poland and Copernicus Memorial Hospital, 93-510 Lodz, Ul. Ciolkowskiego 2, Poland. robaktad@csk.umed.lodz.pl.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intraperitoneal delivery of nanoparticles for cancer gene therapy.
Next Document:  Triptorelin in the management of prostate cancer.